Ten Clinical Tips on COVID-19
for Healthcare Providers Involved in Patient Care
Accessible link: [Link]
Treatment and Prophylaxis
1. The National Institutes of Health has developed guidance on treatment
([Link] which will be regularly
updated as new evidence on the safety and efficacy of drugs and
therapeutics emerges from clinical trials and research publications.
2. There is currently no FDA-approved post-exposure prophylaxis for
people who may have been exposed to COVID-19 ([Link]
coronavirus/2019-ncov/hcp/[Link]).
Symptoms and Diagnosis
3. Non-respiratory symptoms ([Link]
[Link]) of COVID-19 – such as gastrointestinal (e.g., nausea, diarrhea) or
neurologic symptoms (e.g., anosmia, ageusia, headache) – might appear before fever and lower
respiratory tract symptoms (e.g., cough and shortness of breath).
4. Children ([Link] with COVID-19
may have fever and cough at symptom onset as often as adult patients. Although most children
with COVID-19 have not had severe illness, clinicians should maintain a high index of suspicion for
SARS-CoV-2 infection in children, particularly infants and children with underlying conditions.
5. CT scans ([Link] should not be used to screen
for COVID-19 or as a first-line test to diagnose COVID-19. CT should be used sparingly, reserved for
hospitalized, symptomatic patients with specific clinical indications for CT ([Link]
Advocacy-and-Economics/ACR-Position-Statements/Recommendations-for-Chest-Radiography-
and-CT-for-Suspected-COVID19-Infection).
Coinfections
6. Patients can be infected with more than one virus at the same time. Coinfections with other
respiratory viruses ([Link] in people with
COVID-19 have been reported. Therefore, identifying infection with one respiratory virus does not
exclude SARS-CoV-2 virus infection.
7. Several patients with COVID-19 have been reported presenting with concurrent community-acquired
bacterial pneumonia ([Link] Decisions
to administer antibiotics to COVID-19 patients should be based on the likelihood of bacterial infection
(community-acquired or hospital-acquired), illness severity, and antimicrobial stewardship issues
([Link]
Severe Illness
8. Clinicians should be aware of the potential for some patients to rapidly deteriorate ([Link]
coronavirus/2019-ncov/hcp/[Link]) one week after illness onset.
9. The median time to acute respiratory distress syndrome (ARDS) ranges from 8 to 12 days ([Link]
[Link]/coronavirus/2019-ncov/hcp/[Link]).
10. Lymphopenia, neutrophilia, elevated serum alanine aminotransferase and aspartate aminotransferase
levels, elevated lactate dehydrogenase, high CRP, and high ferritin levels may be associated with greater
illness severity ([Link]
[Link]).
[Link]/coronavirus
CS 316791-A 04/30/2020